Skip to main content
. Author manuscript; available in PMC: 2008 Apr 30.
Published in final edited form as: Vaccine. 2007 Jan 24;25(17):3263–3269. doi: 10.1016/j.vaccine.2007.01.073

Table 1.

Adverse Effects after Vaccination with Inactivated Influenza Virus Vaccine With or Without QS21 Adjuvant

No. Subjects with Indicated Severity (0-3)

Aqueous Vaccine QS21 Vaccine


Evaluation Time Adverse Effect 0 1 2 3 0 1 2 3
Day 0 (Observed) Local Pain:1
 Immediate 14 1 0 0 13 2 0 0
 At 30 min 13 2 0 0 5 9 1 0
Day 1 (Observed) Local:
 Pain1 7 8 0 0 2 9 4 0
 Redness2 15 0 0 0 14 1 0 0
 Swelling/induration2 15 0 0 0 14 1 0 0
Systemic:3
 Fever 15 0 0 0 14 15 0 0
 Feverish 15 0 0 0 13 2 0 0
 Headache 14 1 0 0 12 3 0 0
 Fatigue 14 1 0 0 10 5 0 0
 Myalgias 15 0 0 0 10 5 0 0
Days 1-74 (Diary) Local:
 Pain1 7 4 4 0 1 3 11 0
 Redness2 15 0 0 0 13 2 0 0
 Swelling2 15 0 0 0 13 2 0 0
Systemic:3
 Fever 15 0 0 0 14 1 0 0
 Headache 10 4 1 0 9 5 1 0
 Fatigue 11 4 0 0 8 6 1 0
 Myalgias 15 0 0 0 6 6 3 0
 Nausea/vomiting 12 2 1 0 13 2 0 0
1

0 = none, 1 = tender to touch, 2 = hurts to move, 3 = unable to move

2

0 = none, 1 = 0.5 – 5 cm, 2 = 5 – 10 cm, 3 = >10 cm

3

0 = none, 1 = slight/mild, 2 = interferes with activity, 3 = incapacitating

4

Highest severity for day 1-7 interval

5

Temp = 100.6°F

HHS Vulnerability Disclosure